{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:22:13Z","timestamp":1787613733912,"version":"build-2736575974"},"reference-count":63,"publisher":"Georg Thieme Verlag KG","funder":[{"DOI":"10.13039\/100005292","name":"Brigham and Women's Hospital","doi-asserted-by":"crossref","award":["Eleanor and Miles Shore Award"],"award-info":[{"award-number":["Eleanor and Miles Shore Award"]}],"id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"crossref"}]},{"name":"APS Foundation of America"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antiphospholipid antibodies (aPL) are a heterogeneous group of autoantibodies that target phospholipids and phospholipid-binding proteins, and are identified clinically by anticardiolipin, anti-\u03b22-glycoprotein I, or lupus anticoagulant assays. While aPL are a well-established mediator of thrombosis through both proinflammatory and prothrombotic pathways, the role of aPL in arrhythmogenesis including atrial fibrillation (AF) and their association with AF-related thromboembolic outcomes remains poorly defined. In small observational studies, testing positive for aPL has been reported in up to 20% of patients with AF and has been associated with a higher risk of ischemic stroke and other thromboembolic events. In this mini-review, in addition to sharing a succinct summary on prevalence and pathogenicity of aPL in various vascular and thrombotic conditions, we specifically summarize the existing body of literature investigating the association between aPL and AF prevalence and clinical outcomes. Furthermore, we describe the rationale and study design of the TaPL-AF (Thrombophilia with aPL in Atrial Fibrillation) study, an ongoing investigation leveraging Mass General Brigham (MGB) Biobank data to provide evidence on the incidence and prognostic relevance of aPL positivity in AF and explore the impact of aPL on the effectiveness of direct oral anticoagulants in preventing thromboembolic events. These efforts aim to define the clinical relevance of aPL in AF, including their potential role in refining thromboembolic risk stratification and guiding anticoagulation strategies.<\/jats:p>","DOI":"10.1055\/a-2899-3848","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T23:20:28Z","timestamp":1782429628000},"source":"Crossref","is-referenced-by-count":0,"title":["Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL-AF Study Design"],"prefix":"10.1055","author":[{"given":"Bassil","family":"Bacare","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Massachusetts, United States","place":["Boston"],"department":["Department of Medicine, Thrombosis Research Group, Division of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Bukhari","sequence":"first","affiliation":[{"name":"Johns Hopkins University, Maryland, United States","place":["Baltimore"],"department":["Department of Medicine, Division of Cardiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan W.","family":"Watson","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Massachusetts, United States","place":["Boston"],"department":["Department of Medicine, Thrombosis Research Group, Division of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4095-9414","authenticated-orcid":false,"given":"Julia","family":"Malejczyk","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Massachusetts, United States","place":["Boston"],"department":["Department of Medicine, Thrombosis Research Group, Division of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Amalan","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Massachusetts, United States","place":["Boston"],"department":["Department of Medicine, Thrombosis Research Group, Division of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Rashedi","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Massachusetts, United States","place":["Boston"],"department":["Department of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana B.","family":"Pfeferman","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Massachusetts, United States","place":["Boston"],"department":["Department of Medicine, Thrombosis Research Group, Division of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Weber","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Massachusetts, United States","place":["Boston"],"department":["Department of Medicine, Thrombosis Research Group, Division of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Patel","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Massachusetts, United States","place":["Boston"],"department":["Department of Medicine, Thrombosis Research Group, Division of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ruff","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Massachusetts, United States","place":["Boston"],"department":["Department of Medicine, Thrombosis Research Group, Division of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogendra","family":"Kanthi","sequence":"additional","affiliation":[{"name":"National Heart, Lung, and Blood Institute, Maryland, United States","place":["Bethesda"],"department":["Section of Vascular Thrombosis and Inflammation, Division of Intramural Research"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Cushman","sequence":"additional","affiliation":[{"name":"University of Vermont, Larner College of Medicine, Vermont, United States","place":["Burlington"],"department":["Department of Medicine, Division of Hematology Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Knight","sequence":"additional","affiliation":[{"name":"University of Michigan, Michigan, United States","place":["Ann Arbor"],"department":["Department of Internal Medicine, Division of Rheumatology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Massachusetts, United States","place":["Boston"],"department":["Department of Medicine, Thrombosis Research Group, Division of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Costenbader","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Massachusetts, United States","place":["Boston"],"department":["Department of Medicine, Thrombosis Research Group, Division of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Mize","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Massachusetts, United States","place":["Boston"],"department":["Department of Emergency Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Uljon","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Massachusetts, United States","place":["Boston"],"department":["Department of Emergency Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Albert","sequence":"additional","affiliation":[{"name":"Heart and Vascular Institute, Mass General Brigham, Massachusetts, United States","place":["Boston"],"department":["Division of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"University of Liverpool Institute of Ageing and Chronic Disease, Merseyside, United Kingdom of Great Britain and Northern Ireland","place":["Liverpool"],"department":["Liverpool Centre for Cardiovascular Science"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[{"name":"Yale University Center for Outcomes Research and Evaluation, Connecticut, United States","place":["New Haven"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Piazza","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School, Massachusetts, United States","place":["Boston"],"department":["Department of Medicine, Thrombosis Research Group, Division of Cardiovascular Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[{"name":"Yale University Center for Outcomes Research and Evaluation, Massachusetts, United States","place":["Boston"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"issue":"21","key":"ref1","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"D Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"100202","DOI":"10.1016\/j.jtauto.2023.100202","article-title":"Antiphospholipid antibodies induce proinflammatory and procoagulant pathways in endothelial cells","volume":"6","author":"M Patsouras","year":"2023","journal-title":"J Transl Autoimmun"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/art.39247","article-title":"Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome","volume":"67","author":"S Yalavarthi","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00281-022-00916-w","article-title":"Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome","volume":"44","author":"J S Knight","year":"2022","journal-title":"Semin Immunopathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-026-01269-9","article-title":"Antiphospholipid antibodies and cardiovascular thrombosis","author":"S Rashedi","year":"2026","journal-title":"Nat Rev Cardiol"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1055\/a-1701-2809","article-title":"Pathophysiology of antiphospholipid syndrome","volume":"122","author":"D Green","year":"2022","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00296-025-06050-8","article-title":"Antiphospholipid antibodies and atherosclerotic vascular disease: recent advances","volume":"45","author":"A Undas","year":"2025","journal-title":"Rheumatol Int"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"101672","DOI":"10.1016\/j.cpcardiol.2023.101672","article-title":"Risk of subclinical atherosclerosis in patients with antiphospholipid syndrome and subjects with antiphospholipid antibody positivity: a systematic review and meta-analysis","volume":"48","author":"P Karakasis","year":"2023","journal-title":"Curr Probl Cardiol"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13075-022-02814-w","article-title":"Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study","volume":"24","author":"W Qi","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/rheumatology\/keae097","article-title":"Seven-year follow-up atherosclerotic plaque progression in patients with antiphospholipid syndrome versus diabetes mellitus and healthy controls","volume":"64","author":"G Evangelatos","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41591-025-04101-y","article-title":"Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial","volume":"32","author":"L Rivard","year":"2026","journal-title":"Nat Med"},{"issue":"05","key":"ref12","first-page":"634","article-title":"Prothrombotic state in atrial fibrillation patients with one additional risk factor of the CHA2DS2-VASc score (beyond sex)","volume":"35","author":"B G\u0142owicki","year":"2019","journal-title":"Can J Cardiol"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/jth.13690","article-title":"Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis","volume":"15","author":"S van Doorn","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/europace\/euac096","article-title":"Comprehensive comparison of stroke risk score performance: a systematic review and meta-analysis among 6 267 728 patients with atrial fibrillation","volume":"24","author":"V HW van der Endt","year":"2022","journal-title":"Europace"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41569-022-00820-8","article-title":"Epidemiology and modifiable risk factors for atrial fibrillation","volume":"20","author":"A D Elliott","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"15","key":"ref16","doi-asserted-by":"crossref","first-page":"e020157","DOI":"10.1161\/JAHA.120.020157","article-title":"Multiple blood biomarkers and stroke risk in atrial fibrillation: the REGARDS study","volume":"10","author":"M J Singleton","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"ref17","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2012.04.063","article-title":"Inflammation in atrial fibrillation","volume":"60","author":"Y Guo","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"C D Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12959-022-00409-8","article-title":"The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study","volume":"20","author":"W C Yao","year":"2022","journal-title":"Thromb J"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"529075","DOI":"10.3389\/fphys.2020.529075","article-title":"The dynamic interplay between cardiac inflammation and fibrosis","volume":"11","author":"T P Thomas","year":"2020","journal-title":"Front Physiol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s12016-008-8113-y","article-title":"Revisiting Libman-Sacks endocarditis: a historical review and update","volume":"36","author":"J L Lee","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"issue":"08","key":"ref22","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/01.CIR.93.8.1579","article-title":"Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome","volume":"93","author":"M Hojnik","year":"1996","journal-title":"Circulation"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11926-013-0320-8","article-title":"Valvular heart disease in antiphospholipid syndrome","volume":"15","author":"S Zuily","year":"2013","journal-title":"Curr Rheumatol Rep"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.15420\/aer.2020.43","article-title":"Arrhythmias and conduction disturbances in autoimmune rheumatic disorders","volume":"10","author":"S C Plastiras","year":"2021","journal-title":"Arrhythm Electrophysiol Rev"},{"issue":"13","key":"ref25","doi-asserted-by":"crossref","first-page":"e018555","DOI":"10.1161\/JAHA.120.018555","article-title":"Coronary microvascular dysfunction in systemic lupus erythematosus","volume":"10","author":"B N Weber","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"08","key":"ref26","doi-asserted-by":"crossref","first-page":"e014850","DOI":"10.1161\/JAHA.119.014850","article-title":"Coronary endothelial dysfunction is associated with increased risk of incident atrial fibrillation","volume":"9","author":"M T Corban","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.semarthrit.2017.10.015","article-title":"Carotid and femoral atherosclerosis in antiphospholipid syndrome: equivalent risk with diabetes mellitus in a case-control study","volume":"47","author":"E Kravvariti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"18","key":"ref28","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.jacc.2017.02.058","article-title":"Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics","volume":"69","author":"M T Corban","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"ref29","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3390\/cells14131023","article-title":"The interplay between autoimmune disorders affecting the coagulation and platelet systems and their implications for cardiovascular diseases: a systematic review","volume":"14","author":"K Mohammadian","year":"2025","journal-title":"Cells"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"745601","DOI":"10.3389\/fmed.2021.745601","article-title":"Rheumatoid arthritis and cardiovascular risk: retrospective matched-cohort analysis based on the RECORD study of the Italian society for rheumatology","volume":"8","author":"L Argnani","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e17617","DOI":"10.7717\/peerj.17617","article-title":"The association between antiphospholipid syndrome and atrial fibrillation: a single center retrospective case-control study","volume":"12","author":"Z Zhou","year":"2024","journal-title":"PeerJ"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00415-021-10432-w","article-title":"Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic stroke","volume":"268","author":"J S Yoo","year":"2021","journal-title":"J Neurol"},{"issue":"07","key":"ref33","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1212\/WNL.52.7.1368","article-title":"Anticardiolipin antibodies and their associations with cerebrovascular risk factors","volume":"52","author":"D Tanne","year":"1999","journal-title":"Neurology"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1016\/j.jtha.2024.05.038","article-title":"Positive antiphospholipid antibodies increase the risk of ischemic stroke in patients with atrial fibrillation","volume":"22","author":"M Hanarz","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12959-024-00610-x","article-title":"D-dimer and fibrinogen indicate ischemic risk in patients with atrial fibrillation after percutaneous coronary intervention","volume":"22","author":"D Gjermeni","year":"2024","journal-title":"Thromb J"},{"issue":"20","key":"ref36","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth Universal Definition of Myocardial Infarction (2018)","volume":"138","author":"K Thygesen","year":"2018","journal-title":"Circulation"},{"issue":"24","key":"ref37","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"M A Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1055\/a-2664-7887","article-title":"Comparative effectiveness research using randomized trials and observational studies: validity and feasibility considerations","volume":"126","author":"B Bikdeli","year":"2026","journal-title":"Thromb Haemost"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1016\/j.jtha.2025.06.007","article-title":"Improving stroke risk prediction in atrial fibrillation with circulating biomarkers: the CHA2DS2-VASc-Biomarkers model","volume":"23","author":"S AP Short","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1161\/STROKEAHA.118.024305","article-title":"Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores","volume":"50","author":"J M Rivera-Caravaca","year":"2019","journal-title":"Stroke"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1055\/s-0039-1696955","article-title":"The use of biomarkers in clinical management guidelines: a critical appraisal","volume":"119","author":"M A Esteve-Pastor","year":"2019","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1055\/s-0038-1675400","article-title":"Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review","volume":"118","author":"E D Borre","year":"2018","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.mayocp.2020.11.005","article-title":"Atrial fibrillation and endothelial dysfunction: a potential link?","volume":"96","author":"M T Corban","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/01.STR.0000154858.27353.df","article-title":"Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study","volume":"36","author":"D Erdogan","year":"2005","journal-title":"Stroke"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"C Kearon","year":"2016","journal-title":"Chest"},{"issue":"04","key":"ref46","doi-asserted-by":"crossref","first-page":"e236530","DOI":"10.1001\/jamanetworkopen.2023.6530","article-title":"Prevalence of antiphospholipid antibodies and association with incident cardiovascular events","volume":"6","author":"Y Zuo","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00000658-199410000-00012","article-title":"Antiphospholipid antibodies in vascular surgery patients. A cross-sectional study","volume":"220","author":"L M Taylor Jr","year":"1994","journal-title":"Ann Surg"},{"issue":"03","key":"ref48","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1078-5884(05)80131-5","article-title":"Lupus anticoagulant in patients with peripheral vascular disease: a prospective study","volume":"9","author":"L J Fligelstone","year":"1995","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0741-5214(96)70068-X","article-title":"Prospective comparison of infrainguinal bypass grafting in patients with and without antiphospholipid antibodies","volume":"24","author":"R W Lee","year":"1996","journal-title":"J Vasc Surg"},{"issue":"03","key":"ref50","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1078-5884(97)80188-8","article-title":"Antibodies to cardiolipin may increase the risk of failure of peripheral vein bypasses","volume":"14","author":"T G Nielsen","year":"1997","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"08","key":"ref51","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0002-9343(00)00600-8","article-title":"Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease","volume":"109","author":"F Puisieux","year":"2000","journal-title":"Am J Med"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijcard.2019.10.042","article-title":"Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population","volume":"300","author":"C Selmi","year":"2020","journal-title":"Int J Cardiol"},{"issue":"05","key":"ref53","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1067\/mva.2001.115163","article-title":"Relationship between antiphospholipid antibodies and progression of lower extremity arterial occlusive disease after lower extremity bypass operations","volume":"33","author":"E Y Lam","year":"2001","journal-title":"J Vasc Surg"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"102832","DOI":"10.1016\/j.jaut.2022.102832","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study","volume":"129","author":"T Bucci","year":"2022","journal-title":"J Autoimmun"},{"issue":"05","key":"ref55","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s10067-022-06056-8","article-title":"Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers-cross-sectional study of Serbian cohort","volume":"41","author":"A Djokovic","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"02","key":"ref56","first-page":"234","article-title":"Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study","volume":"31","author":"L Stojanovich","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"ref57","volume-title":"Ischemic Stroke","author":"F Lui","year":"2025"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"1901647","DOI":"10.1183\/13993003.01647-2019","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)","volume":"54","author":"S V Konstantinides","year":"2019","journal-title":"Eur Respir J"},{"issue":"22","key":"ref59","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/jama.2025.15222","article-title":"Superficial vein thrombosis: a review","volume":"334","author":"G Piazza","year":"2025","journal-title":"JAMA"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"45","author":"L Norgren","year":"2007","journal-title":"J Vasc Surg"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-981-15-2517-9_3","article-title":"Revascularization for coronary artery disease: principle and challenges","volume":"1177","author":"D Gu","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"ref62","volume-title":"Percutaneous Coronary Intervention","author":"M Ahmad","year":"2025"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"e002325","DOI":"10.1136\/bmjdrc-2021-002325","article-title":"Lower extremity reamputation in people with diabetes: a systematic review and meta-analysis","volume":"9","author":"R Liu","year":"2021","journal-title":"BMJ Open Diabetes Res Care"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2899-3848.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:49:17Z","timestamp":1787611757000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2899-3848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":63,"URL":"https:\/\/doi.org\/10.1055\/a-2899-3848","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,25]]},"published":{"date-parts":[[2026,6,25]]}}}